Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels By Ogkologos - August 4, 2026 91 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RxPONDER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC MOST POPULAR Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed... May 31, 2023 FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative... February 27, 2025 FDA Approves Crizotinib for ALK-positive Inflammatory Myofibroblastic Tumour July 25, 2022 How Running and Training for a Marathon Helped Me Cope After... August 22, 2023 Load more HOT NEWS Scientists Link a Single Type of Bacteria to Colorectal Cancer Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with... A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target... Study Shows Supplements Increase Risk of Relapse and Death in Breast...
